Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality
lantern pharma與明星治療公司共同展示LP-184 (科創板-001) 第10億階段試驗設計和膠質母細胞瘤的臨床前數據，重點介紹新型合成致死性
